Manager TitleAgeSince
Chief Executive Officer 53 -
Director of Finance/CFO 67 -
General Counsel 65 -
Date Insider Type Main position Quantity % Market Cap.
16/04/21 Free

Chief Financial Officer

569,947 1.2238%
16/04/21 Issuer sale

Controller/Auditor

88,423 0.1899%
16/04/21 Issuer sale

Chief Executive Officer

548,971 1.1788%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%+0.16% - - 1.74B
+0.93%+6.97%+59.60%+68.35% 57.28B
-1.92%+6.03%+40.64%+83.42% 54.99B
-0.46%-1.29%+2.86%+428.78% 23.18B
-2.97%-2.35%-22.53%-16.40% 22.59B
-0.36%+5.73%+24.13%-6.24% 20.46B
-1.34%+0.51%+26.03%-29.41% 17.56B
-1.44%+5.67%+38.77%+504.71% 15.67B
-1.30%-5.02%+170.77%+291.37% 14.46B
-0.50%-0.98%+21.43%+180.07% 13.92B
Average -0.93%+1.28%+40.19%+167.18% 26.68B
Weighted average by Cap. -0.87%+2.10%+39.70%+133.49%
Logo Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's primary focus is on researching and developing immuno-oncology and targeted cancer therapies. The Company's pipeline includes Bemarituzumab (FPA144), which is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that it is studying in a clinical trial in combination with 5-fluorouracil (5-FU), leucovorin and oxaliplatin; FPA150, which is a CD8 T cell checkpoint inhibitor antibody that targets B7-H4; FPT155, which is a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28; Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials, and BMS-986258, which is an anti-T cell immunoglobulin and mucin domain-3, or TIM-3 antibody.
Employees
51
  1. Stock Market
  2. Stocks
  3. FPRX Stock